<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="179">
  <stage>Registered</stage>
  <submitdate>1/11/1999</submitdate>
  <approvaldate>1/11/1999</approvaldate>
  <nctid>NCT00003321</nctid>
  <trial_identification>
    <studytitle>Quality-of-Life Assessment of Patients Who Have Cancer of the Esophagus</studytitle>
    <scientifictitle>An International Field Study of the Reliability and Validity of the EORTC-QLQ-C30 and a Disease Specific Questionnaire Module (the EORTC OES-24) in Assessing the Quality of Life of Patients With Oesophageal Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EORTC-15961/40973</secondaryid>
    <secondaryid>EORTC-15961-40973</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Esophageal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Oesophageal (gullet)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - psychosocial assessment and care
Treatment: surgery - quality-of-life assessment

Treatment: surgery: psychosocial assessment and care


Treatment: surgery: quality-of-life assessment


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS: Group I: Local or locoregional primary esophageal or
        esophago-gastric cancer Planned esophagectomy with or without adjuvant or neoadjuvant
        chemotherapy and/or radiotherapy OR Planned radical radiotherapy with or without
        chemotherapy Prior endoscopic procedure to relieve dysphagia allowed No distant liver or
        bone metastasis if undergoing esophagectomy Group II: Metastatic esophageal cancer or local
        anastomotic recurrence of esophageal cancer or deemed unsuitable for esophagectomy Prior
        palliation by endoscopic or open intubation, laser treatment, tumor necrosis with alcohol
        injection or diathermy, or intraluminal radiotherapy allowed Prior palliative radiotherapy
        or chemotherapy allowed No cerebral metastases

        PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Life expectancy:
        Group I: At least 3 months Group II: At least 4 weeks Hematopoietic: Not specified Hepatic:
        Not specified Renal: Not specified Other: Mentally fit to complete a questionnaire or
        undergo an interview Aware of diagnosis No concurrent second malignancy except basal cell
        skin cancer No concurrent participation in other quality-of-life studies

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics
        Surgery: See Disease Characteristics</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/1998</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>370</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Sir Charles Gairdner Hospital, Perth - Perth</hospital>
    <postcode>6009 - Perth</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Brieux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les-Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Marburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Bergen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Pamplona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Gothenburg (Goteborg)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>European Organisation for Research and Treatment of Cancer - EORTC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Questionnaires that measure quality of life may improve the ability to plan
      treatment for patients who have cancer of the esophagus.

      PURPOSE: This clinical trial studies quality-of-life assessments of patients with cancer of
      the esophagus who are receiving treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00003321</trialwebsite>
    <publication>Conroy T, Etienne PL, Adenis A, Ducreux M, Paillot B, Oliveira J, Seitz JF, Francois E, Van Cutsem E, Wagener DJ, Kohser F, Daamen S, Praet M, Gorlia T, Baron B, Wils J; European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol. 2002 May;13(5):721-9.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jane Blazeby, MB, CHB, FRCS, BSc, MD</name>
      <address>University Hospitals Bristol NHS Foundation Trust</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>